BioInvent International
27.50 SEK
+7.21 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.
Read moreRevenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
Interim report Q2'26
Interim report Q3'26
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCO
BioInvent anordnar ett digitalt KOL-event för att diskutera BI-1808 för behandling av äggstockscancer, den 27 maj 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits